We read with interest and great concerns the paper by Dinesh et al. 1 in Genes and Immunity. The paper concerns the potential role of the Ifi202b gene (encoding for the p202b protein) in CD8 þ T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB Â NZW)F 1 lupusprone mice. In the paper, authors state that 'the candidate lupus susceptibility gene Ifi202a is largely dispensable for B cell function.' This statement is misleading because in the Ifi202a knockout mice (and in cells from the mice), a highly homologous gene, the Ifi202b (encoding for the p202b protein), is expressed and its expression is upregulated. 2 Moreover, both Ifi202a and Ifi202b genes are co-expressed in mouse organs and in immune cells.
2,3
The p202a and p202b proteins differ by seven amino acids residues (out of 445 residues) in the N-terminus. 2 These minor differences in the amino acids residues between p202a and p202b proteins could account for the lack of a phenotype in the Ifi202a knockout mice. 2 Accordingly, it is expected that the knockdown of the Ifi202b gene expression in cells will not result in a phenotype. Given that the authors do not provide any experimental evidence for the expression (or the lack of it) of the Ifi202a gene in CD8 þ cells from the (NZB Â NZW)F 1 lupus-prone mice, and their experimental conditions to detect the levels of the Ifi202b mRNA and protein cannot distinguish between the Ifi202a and Ifi202b mRNAs and proteins (see below), the main conclusion of the study that 'interferon-inducible gene 202b controls CD8 þ T cell-mediated suppression in anti-DNA Ig peptide-treated (NZB Â NZW)F 1 lupus mice' is incorrect.
Commercially available p202 antibodies cannot distinguish between the p202a and p202b proteins. 3, 4 Moreover, these antibodies cross-react with other proteins. 4 Given that the authors do not provide any details concerning the p202 antibodies that they used (purchased from Santa Cruz Biotechnology, Santa Cruz, CA, USA), and their experiments do not include appropriate controls to demonstrate the specificity of p202 antibodies, therefore, the identity of the protein band that authors detected remains unclear. Furthermore, immunoblotting data (for example, figures 1e, f and g) to show increases in the 'p202b' protein levels are not convincing; increased protein amounts are seen in the lanes as compared with 'control' lanes.
We are intrigued by the nucleotide sequence of the primer pair that was used by the authors to detect steady-state levels of the 'Ifi202b' mRNA in their studies. The sequence is not specific to the Ifi202b gene (because a nucleotide blast using the nucleotide sequence in the paper did not return the Ifi202b gene-specific sequences in the NCBI data base). Therefore, the significance of the experimental observations using the primer pair, which may not be specific to the Ifi202b gene, remains unclear.
In summary, we think that the main conclusions of the paper by Dinesh et al. 1 are not supported by the experimental data.
